Pilot study of topotecan and high-dose cyclophosphamide for resistant pediatric solid tumors Academic Article Article uri icon

Overview

MeSH Major

  • Bone Neoplasms
  • Osteosarcoma

abstract

  • Its antitumor potential and limited toxicity make HD-Cy/Topo an attractive choice for inclusion in aggressive salvage programs aimed at achieving cures of resistant tumors. It may also merit incorporation into frontline treatment protocols.

publication date

  • November 20, 2000

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1002/1096-911X(20001101)35:5<468::AID-MPO5>3.0.CO;2-P

PubMed ID

  • 11070479

Additional Document Info

start page

  • 468

end page

  • 74

volume

  • 35

number

  • 5